BZW1 Inhibitors
BZW1, also known as BZW2 or TRIP-Br2, is a transcriptional regulator implicated in cell proliferation, differentiation, and tumorigenesis. This protein functions as a transcriptional coactivator, interacting with various transcription factors to modulate the expression of genes involved in cell cycle progression and oncogenesis. Through its association with transcription factors such as E2F, BZW1 exerts control over the transcriptional machinery, influencing the expression of genes crucial for cell proliferation and survival.
The inhibition of BZW1 is primarily achieved through targeting the insulin-like growth factor 1 receptor (IGF-1R) signaling pathway, which plays a pivotal role in regulating cell growth and proliferation. Chemical inhibitors targeting IGF-1R disrupt downstream signaling cascades involved in BZW1 expression, indirectly down-regulating its activity. By interfering with IGF-1R signaling, these inhibitors modulate the transcriptional landscape, ultimately leading to the inhibition of BZW1-mediated transcriptional coactivation. This inhibition strategy provides a promising avenue for the development of interventions targeting aberrant cell proliferation and oncogenic processes associated with dysregulated BZW1 activity.
Items 1 to 10 of 18 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
IGF-1R inhibitor targeting the insulin-like growth factor 1 receptor, indirectly down-regulating BZW1 by inhibiting upstream signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets BCR-ABL kinase, used in chronic myeloid leukemia to block aberrant signaling. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $146.00 $265.00 | 1 | |
Dual IGF-1R/IR inhibitor impacting insulin-like growth factor 1 receptor and insulin receptor signaling, leading to inhibition of BZW1 expression via downstream signaling modulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases including RAF and VEGFR, used in advanced renal and hepatocellular carcinoma. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
IGF-1R inhibitor suppressing insulin-like growth factor 1 receptor signaling, ultimately inhibiting BZW1 expression through downstream pathway interference. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Targets androgen receptors, used to treat advanced prostate cancer by blocking androgen signaling. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Selectively inhibits EGFR kinase with T790M mutation, used in non-small cell lung cancer resistant to other EGFR inhibitors. | ||||||
GSK1838705A | 1116235-97-2 | sc-364502 sc-364502A | 5 mg 50 mg | $240.00 $992.00 | ||
IGF-1R/IR inhibitor disrupting insulin-like growth factor 1 receptor and insulin receptor signaling, resulting in down-regulation of BZW1 expression via inhibition of downstream cascades. | ||||||
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $138.00 $203.00 $895.00 | 63 | |
IGF-1R inhibitor impacting insulin-like growth factor 1 receptor signaling, thereby indirectly suppressing BZW1 expression through modulation of downstream pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK kinase, used in B-cell malignancies to block B-cell receptor signaling. | ||||||